Effective delivery of large genes to the retina by dual AAV vectors

Ivana Trapani, Pasqualina Colella, Andrea Sommella, Carolina Iodice, Giulia Cesi, Sonia de Simone, Elena Marrocco, Settimio Rossi, Massimo Giunti, Arpad Palfi, Gwyneth Jane Farrar, Roman Polishchuk, Alberto Auricchio

View at source ↗PDF ↗Article269 citations

Abstract

Retinal gene therapy with adeno-associated viral (AAV) vectors is safe and effective in humans. However, AAV's limited cargo capacity prevents its application to therapies of inherited retinal diseases due to mutations of genes over 5 kb, like Stargardt's disease (STGD) and Usher syndrome type IB (USH1B). Previous methods based on 'forced' packaging of large genes into AAV capsids may not be easily translated to the clinic due to the generation of genomes of heterogeneous size which raise safety concerns. Taking advantage of AAV's ability to concatemerize, we generated dual AAV vectors which reconstitute a large gene by either splicing (trans-splicing), homologous recombination (overlapping), or a combination of the two (hybrid). We found that dual trans-splicing and hybrid vectors transduce efficiently mouse and pig photoreceptors to levels that, albeit lower than those achieved with a single AAV, resulted in significant improvement of the retinal phenotype of mouse models of STGD and USH1B. Thus, dual AAV trans-splicing or hybrid vectors are an attractive strategy for gene therapy of retinal diseases that require delivery of large genes.

Abstract of "Effective delivery of large genes to the retina by dual AAV vectors" by Ivana Trapani, Pasqualina Colella, Andrea Sommella et al., https://doi.org/10.1002/emmm.201302948, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.

Record

Archive ID
doi:10.1002/emmm.201302948
Published
Oct 22, 2013
Venue
EMBO Molecular Medicine
DOI
10.1002/emmm.201302948
PubMed
24150896
Categories
Virus-based gene therapy research
License
cc-by
Provenance
openalex

Topics